Real-world outcomes of 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: the KuPSMALu trial in Eastern Finland
In-house ¹⁷⁷Lu-PSMA-I&T production combined with pragmatic imaging-based patient selection provides a safe, cost-effective therapy for mCRPC in public healthcare. PSA kinetics, particularly PSA dt, are strong predictors of therapeutic benefit. The findings align with VISION and TheraP trials and highlight the feasibility of integrating radioligand therapy into routine clinical care.
Authors
- Kirsi Ketola (ORCID: https://orcid.org/0000-0001-6484-9861)
- Päivi Auvinen (ORCID: https://orcid.org/0000-0002-2392-9395)
- Pekka Poutiainen (ORCID: https://orcid.org/0000-0001-8148-9909)
- Heidi Gröhn (ORCID: https://orcid.org/0009-0002-7906-4260)
- Okko‐Sakari Kääriäinen (ORCID: https://orcid.org/0000-0002-2905-6310)
- Hanna Mussalo (ORCID: https://orcid.org/0000-0002-9470-6930)
- Satu Pukkila
- Timo Voivalin
Institutions
- University of Eastern Finland (FI)
- Kuopio University Hospital (FI)
- Emergency Services College (FI)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-11-11
- DOI
- https://doi.org/10.2340/1651-226x.2025.44748
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kuopion Yliopistollinen Sairaala
- Sigrid Juséliuksen Säätiö
- Instrumentariumin Tiedesäätiö
- Syöpäsäätiö